Back to all assets

Dexcom DXCM

equity

Price History

$0.500$52.27$104.04$155.8
2005-04 · DCA start$2.5

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-92.1%-61.4%-30.7%0.0%
2005-042026-08 · -41.7%

Worst drawdown: −92%, peaking Apr 2006 and bottoming Nov 2008 — 88 months below the prior high before recovering.

DCA Backtest

Invested
$25,700
Value today
$454,869
Return
+1669.9%
Months invested
257

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $35,042 today, so the real (inflation-adjusted) return is +1198.1%.

Lump sum instead — $25,700 all at once in Apr 2005: $933,424 (+3532.0%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Oct 2021): $6,017 on $5,900 invested (+2.0%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2005-04: +1669.9%

About Dexcom

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S., and manufacturing facilities in Mesa, Arizona, U.S.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. (Wikipedia)

It's a listed company categorised under health care and health care equipment, with a market cap of about $34.3B.

It rates Medium-High Risk at 2.4/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: market / volatility (4.0/5) and earnings quality (3.0/5).

Scoring well: leverage / financial at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.4/5)80% rated

How these ratings work

Market / Volatility4.0/5 · weight 20%
  • Annualised volatility (3yr)4/549.9
  • Max drawdown from ATH5/592.1
  • Beta vs S&P 5003/51.0
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5432.0m
  • Float % of shares outstandingnot yet researched
Leverage / Financial1.0/5 · weight 20%
  • Debt / equitynot yet researched
  • Interest coverage (EBIT / interest)1/563.8
Earnings Quality3.0/5 · weight 15%
  • 3yr EPS volatility3/526.8
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.